Last reviewed · How we verify

NCT06213493: BACE1AS-HF

Bace1as Role in Heart Failure (BACE1AS-HF)

Completed Last updated 30 April 2025
What this trial tests

trial testing measurement of RNAs in Heart Failure in 630 participants. Completed in 30 November 2024.

Timeline
12 March 2021
Primary endpoint
30 November 2024
30 November 2024

Quick facts

Lead sponsorIRCCS Policlinico S. Donato
StatusCompleted
Study typeOBSERVATIONAL
Enrollment630
Start date12 March 2021
Primary completion30 November 2024
Estimated completion30 November 2024
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS Policlinico S. Donato

Who can join

Adults 18 to 75, any sex, with Heart Failure or Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this project is 1) to explore the clinical relevance of BACE1-AS and BACE1 as therapeutic targets and 2) to evaluate their potentiality as biomarkers in ischemic heart failure (HF). The first aim will be studied by validating in left ventricle biopsies in patients with post-ischemic heart failure the transcriptome and DNA methylation status data obtained in cell lines where the expression of BACE1-AS has been modulated. The investigation of BACE1-AS and BACE1 as biomarkers will be obtained by using peripheral blood mononuclear cells (PBMCs) from patients with acute coronary syndrome (ACS) treated with percutaneous angioplasty (PCI) procedure and undergoing to left ventricular remodeling. Furthermore, PBMCs from patients with chronic ischemic HF recruited from the Istituti Clinici Scientifici Maugeri Pavia will be also used. From the data obtained from these patients and from non-decompensated subjects, the levels of BACE1-AS and BACE1 in the blood will be measured and correlated with each other and with β-amyloid levels (βA), as well as with clinically relevant parameters.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Noncoding RNA Contribution to Aging and Lifespan.
    Ugalde AP, Roiz-Valle D, Moledo-Nodar L, Caravia XM, et al · · 2024 · cited 10× · PMID 38394352 · DOI 10.1093/gerona/glae058
  2. Molecular Diagnostics in Heart Failure: From Biomarkers to Personalized Medicine.
    Țica O, Țica O. · · 2025 · cited 8× · PMID 40722556 · DOI 10.3390/diagnostics15141807
  3. The Relevance of the Accurate Annotation of Micro and Long Non-Coding RNA Interactions for the Development of Therapies.
    Panni S. · · 2025 · cited 2× · PMID 40149414 · DOI 10.3390/genes16030262

Verify or expand the search:

Other trials of measurement of RNAs

Trials testing the same drug.

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other IRCCS Policlinico S. Donato trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06213493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing